<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339285</url>
  </required_header>
  <id_info>
    <org_study_id>14-1622</org_study_id>
    <secondary_id>5R01MH101547-02</secondary_id>
    <nct_id>NCT02339285</nct_id>
  </id_info>
  <brief_title>Transcranial Alternating Current Stimulation for Major Depressive Disorder</brief_title>
  <acronym>MDD</acronym>
  <official_title>Pilot Clinical Trial for the Evaluation of Feedback Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the effects of non-invasive transcranial alternating current stimulation (tACS)
      on patients with Major Depressive Disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Hypothesis: Non-invasive brain stimulation that suppresses alpha oscillation reduces
      cortical hyperactivity and causes a clinical improvement

      Aim 1: To conduct a pilot clinical trial to establish feasibility and to collect first
      effectiveness data for the use of tACS to renormalize pathological alpha oscillations in the
      dorsolateral prefrontal cortex (dl-pfc) of unmedicated patients with MDD by comparing MADRS
      scores from baseline and one month follow up.

      Aim 2: Compare alpha oscillation power from resting state EEG recordings on the first and
      last day of stimulation. Collect EEG data at the one month follow up visit using this data to
      analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2015</start_date>
  <completion_date type="Actual">June 19, 2017</completion_date>
  <primary_completion_date type="Actual">June 19, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Montgomery-Asberg Depression Rating Scale (MADRS) will be the primary outcome measures for this study</measure>
    <time_frame>5 weeks from baseline measure</time_frame>
    <description>The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. This measurement will be taken at baseline (first day of stimulation), last day of stimulation, at the 3 week and at the 5 week follow up visits. A comparison of MADRS scores between baseline and 5 week follow up is the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare alpha oscillation power from resting state EEG recordings on the first and last day of stimulation</measure>
    <time_frame>5 days from baseline measure (day 5)</time_frame>
    <description>EEG includes resting state and N-back tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare alpha oscillation power from resting state EEG recordings on the first of stimulation to the 5 week follow up visit</measure>
    <time_frame>5 weeks from baseline measure</time_frame>
    <description>EEG includes resting state and N-back tasks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>5 days from baseline measure (day 5) and 5 weeks from baseline measure</time_frame>
    <description>The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. This measurement will be taken at baseline (first day of stimulation), last day of stimulation, at the 3 week and at the 5 week follow up visits. We will compare the scores between baseline and 5 week follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment (MOCA)</measure>
    <time_frame>5 days from baseline measure (day 5) and 5 weeks from baseline measure</time_frame>
    <description>This measurement will be taken at baseline (first day of stimulation) and at the 5 week follow up visits. We will compare the scores between baseline and 5 week follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>5 days from baseline measure (day 5) and 5 weeks from baseline measure</time_frame>
    <description>This measurement will be taken at baseline (first day of stimulation), last day of stimulation, at the 3 week and at the 5 week follow up visits. We will compare the scores between baseline and 5 week follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impressions (CGI)</measure>
    <time_frame>5 days from baseline measure (day 5) and 5 weeks from baseline measure</time_frame>
    <description>This measurement will be taken at baseline (first day of stimulation), last day of stimulation, at the 3 week and at the 5 week follow up visits. We will compare the scores between baseline and 5 week follow up.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>MDD</condition>
  <arm_group>
    <arm_group_label>tACS (alpha)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 participants: 10Hz tACS with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tACS (gamma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 participants: 40Hz tACS with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>30 participants: Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tACS (alpha)</intervention_name>
    <arm_group_label>tACS (alpha)</arm_group_label>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tACS (gamma)</intervention_name>
    <arm_group_label>tACS (gamma)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-65 years old

          -  DSM-IV diagnosis of MDD; unipolar, non-psychotic

          -  Hamilton Depression Rating Scale score &gt;8

          -  Capacity to understand all relevant risks and potential benefits of the study
             (informed consent)

          -  Meet criteria for low suicide risk

          -  Willing to comply with all study procedures and be available to do so for the duration
             of the study

          -  Women of reproductive potential must use highly effective contraception

        Exclusion Criteria:

          -  DSM-IV diagnosis of alcohol of substance abuse (other than nicotine) within the last
             month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine)
             within the last 6 months

          -  Current use of benzodiazepines or anti-epileptic drugs

          -  Current axis I mood, or psychotic disorder other than major depressive disorder

          -  Lifetime comorbid psychiatric bipolar or psychotic disorder

          -  Eating disorder (current or within the past 6 months)

          -  Obsessive-compulsive disorder (lifetime)

          -  PTSD (current or within the last 6 months)

          -  ADHD (currently under treatment)

          -  Anything that, in the opinion of the investigator, would place the participant at
             increased risk or preclude the participant's full compliance with or completion of the
             study

          -  Neurological disorders, including but not limited to history of seizures (except
             childhood febrile seizures and ECT induced seizures), dementia, history of stroke,
             Parkinson's disease, multiple sclerosis, cerebral aneurism

          -  Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or
             renal impairment) or treatment for a medical disorder that could interfere with study
             participation

          -  History of traumatic brain injury, reoccurring seizures or later cognitive
             rehabilitation, or causing cognitive sequelae

          -  Prior brain surgery

          -  Any brain devices/implants, including cochlear implants and aneurysm clips

          -  Co-morbid neurological condition (i.e. seizure disorder, brain tumor)

          -  Non English speakers

          -  Pregnancy, nursing, or if female and fertile, unwilling to use appropriate birth
             control measures during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Frohlich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina at Chapel Hill, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Chapel Hill Medical School Wing C</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Valiengo L, Bense√±or IM, Goulart AC, de Oliveira JF, Zanao TA, Boggio PS, Lotufo PA, Fregni F, Brunoni AR. The sertraline versus electrical current therapy for treating depression clinical study (select-TDCS): results of the crossover and follow-up phases. Depress Anxiety. 2013 Jul;30(7):646-53. doi: 10.1002/da.22079. Epub 2013 Apr 26.</citation>
    <PMID>23625554</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tACS</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>mood symptoms</keyword>
  <keyword>sham</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

